Chemically induced sarcomas in Sprague-Dawley rats: dose effects on autoantibody levels and tumor progression.
We previously reported that a single injection of 2 mg benzo[a]pyrene (B[a]P) induced seric anti-phosphatidylinositol (PtdIns) autoantibodies (autoAb) and highly malignant sarcomas with 100% efficiency in Sprague-Dawley (SD) female rats. To evaluate the effects of lower doses, we administered a single dose (from 0.125 to 1 mg) of B[a]P into such rats. In all cases, we noted significantly high levels of anti-PtdIns autoAb, with clinically palpable tumors appearing around Day 100. Tumors grew more slowly than they did in the previous model (2 mg B[a]P). Both anti-PtdIns autoAb levels and first appearance of the tumor seemed to be independent of carcinogen doses. Conversely, tumor evolution seemed to depend on B[a]P doses.
Faiderbe
S
S
Immunology and Pathology Lab, University of Bordeaux II, France.
Chagnaud
J L
JL
Geffard
M
M
D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000097:blood; D000912:Antibodies, Neoplasm / Q000097:blood; D001323:Autoantibodies / Q000097:blood*; D001564:Benzo(a)pyrene; D015197:Carcinogenicity Tests; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D010716:Phosphatidylinositols / Q000276:immunology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012513:Sarcoma, Experimental / Q000139:chemically induced / Q000276:immunology*
D017152:Antibodies, Antiphospholipid; D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D010716:Phosphatidylinositols; D001564:Benzo(a)pyrene